Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant nivolumab with or without denosumab for resectable NSCLC
ACTRN12618001121257Phase 2Recruiting
- Sponsor
- Royal Brisbane and Women's Hospital
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Nivolumab alone with Nivolumab plus denosumab (2 arms). Primary endpoint: Pharmacodynamic correlates of neoadjuvant therapy. Started May 2019; status: recruiting.
02
Drugs
nivolumabdenosumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ACTRN12618001121257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001121257.